First in human, single arm, single center, open-label, proof of concept study to evaluate the safety and tolerability of infusing HSC835 (LFU835-expanded umbilical cord blood hematopoietic stem cells)in patients with hematological malignancies.
|Effective start/end date||8/1/11 → 11/2/16|
- NOVARTIS PHARMACEUTICALS CORPORATION
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.